

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**GRANT OF RESTRICTED SHARES UNDER
RESTRICTED SHARE AWARD SCHEME**

The Board is pleased to announce that on March 25, 2026, it has approved the grant of 25,575,356 RSA Restricted Shares, subject to acceptance of the Grantees, pursuant to the Restricted Share Award Scheme. Details of the RSA Grant are set out as follows:

Grant Date:	March 25, 2026
Number of RSA Restricted Shares Granted:	25,575,356 RSA Restricted Shares to 1,946 Grantees (of which 2 Grantees are Directors, 1 Grantee is an associate of a Director and the remaining 1,943 Grantees are employees of the Group)
Purchase Price for the RSA Restricted Shares Granted:	Nil
Market Price of the Shares on the Grant Date:	HK\$33.14 per Share
Vesting Period:	25% of the total RSA Restricted Shares granted shall vest on each of the first, second, third and fourth anniversary of the Grant Date respectively.

Clawback Mechanism: Pursuant to the terms of the Restricted Share Award Scheme, upon the occurrence of any of the following event in relation to a selected participant under the Restricted Share Award Scheme where (a) the selected participant's service or employment with the Group has been terminated by any member of the Group for cause as defined in the Restricted Share Award Scheme; or (b) the selected participant has been convicted for any criminal offence involving his or her integrity or honesty, then the Board may make a determination at its absolute discretion that: (A) any unvested RSA Restricted Shares shall immediately lapse, (B) with respect to any RSA Restricted Shares issued or transferred to that selected participant, the selected participant shall be required to transfer back to the Company or its nominee (1) the equivalent number of Shares, (2) an amount in cash equal to the market value of such Shares, or (3) a combination of (1) and (2), and/or (C) with respect to any RSA Restricted Shares held by the trustee of the Restricted Share Award Scheme for the benefit of the selected participant, those RSA Restricted Shares shall no longer be held on trust for nor inure to the benefit of the selected participant.

Performance Target(s): A time-based vesting schedule is applicable to the RSA Grant with no performance target attached.

The RSA Restricted Shares granted serves as discretionary bonus in recognition of the Grantees' past contributions to the Group and forms part of their remuneration package for their services provided to the Group. The RSA Restricted Shares will also give the Grantees an opportunity to have a personal stake in the Company and will help motivate the Grantees in optimizing their performance and efficiency. The number of RSA Restricted Shares granted is based on the work performance and potential of the Grantees and no additional performance target is imposed before the RSA Restricted Shares are vested to the Grantees. In view of the above and in line with the previous customary practice of the Company in terms of equity-based remuneration, the Remuneration Committee considered the grant of RSA Restricted Shares are in alignment with the purposes of the Restricted Share Award Scheme.

Among the 25,575,356 Restricted Shares granted as referred to above, 2,041,426 Restricted Shares were granted to 2 Grantees who are Directors and 1 Grantee who is an associate of a Director, with details as follows:

Name	Position	Number of Restricted Shares Granted
Dr. Zhisheng Chen	Executive Director and chief executive officer of the Company	1,442,769 ⁽¹⁾
Dr. Sherry Xuejun Gu	Executive Director, chief technology officer and executive vice president of the Company	543,819 ⁽¹⁾
Ms. Yan Zhao ⁽²⁾	Senior director of the internal audit department of the Company	54,838 ⁽³⁾
Total		<u><u>2,041,426</u></u>

Notes:

- (1) The grant to each of Dr. Zhisheng Chen and Dr. Sherry Xuejun Gu serves as a discretionary bonus in recognition of their contributions to the Group for the financial year ended December 31, 2025.
- (2) Ms. Yan Zhao is the spouse of Dr. Zhisheng Chen.
- (3) The grant to Ms. Yan Zhao serves as a discretionary bonus in recognition of her contributions to the Group for the two financial years ended December 31, 2024 and December 31, 2025.

LISTING RULES IMPLICATIONS

The RSA Grant will not be subject to approval by the Shareholders, and save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company or an associate of any of them.

The RSA Grant would not result in the Shares issued and to be issued in respect of all share options and share awards granted to each individual Grantee in the 12-month period up to and including the Grant Date in aggregate to exceed 1% of the Shares in issue.

The RSA Grant to 2 Grantees who are Directors and 1 Grantee who is an associate of a Director would not result in the Shares issued and to be issued in respect of all share awards granted to each of Dr. Zhisheng Chen, Dr. Sherry Xuejun Gu and Ms. Yan Zhao in the 12-month period up to and including the Grant Date in aggregate to exceed 0.1% of the Shares in issue.

The grant of RSA Restricted Shares has been approved by the Board (including independent non-executive Directors), save that (i) Dr. Zhisheng Chen abstained from approving the relevant resolutions relating to the grant of RSA Restricted Shares to himself and Ms. Yan Zhao; and (ii) Dr. Sherry Xuejun Gu abstained from approving the relevant resolutions relating to the grant of RSA Restricted Shares to herself.

Taking into account the purposes and objectives of the Restricted Share Award Scheme, the Company considers that the RSA Grant is fair and reasonable, and is in the interests of the Company and its Shareholders as a whole.

As at the date of this announcement and following the RSA Grant, 165,868,231 Restricted Shares will be available for future grants under the Scheme Mandate Limit.

DEFINITIONS

“associate”	has the meaning ascribed thereto under the Listing Rules
“Board”	the board of Directors of the Company
“Company”	WuXi Biologics (Cayman) Inc. (藥明生物技術有限公司*), an exempted company incorporated in the Cayman Islands with limited liability on February 27, 2014
“Director(s)”	the director(s) of the Company
“Global Partner Program Share Scheme”	the share award scheme for global partner program adopted by the Company on June 16, 2021 and amended and restated on June 27, 2023
“Grantee(s)”	the grantees who were awarded the RSA Restricted Shares in accordance with the Restricted Share Award Scheme on March 25, 2026
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time

“Remuneration Committee”	the remuneration committee of the Board
“Restricted Share(s)”	any Share(s) that may be offered by the Company to any eligible participants pursuant to the Restricted Share Award Scheme and/or the Global Partner Program Share Scheme
“Restricted Share Award Scheme”	the restricted share award scheme adopted by the Company on January 15, 2018 and amended and restated on June 27, 2023
“RSA Grant”	grant of the RSA Restricted Shares to the Grantees on March 25, 2026
“RSA Restricted Shares”	Restricted Shares offered by the Company pursuant to the Restricted Share Award Scheme
“Scheme Mandate Limit”	254,904,706 Shares, being the maximum number of Shares which may be issued and allotted in respect of all Restricted Shares to be granted under the Restricted Share Award Scheme and the Global Partner Program Share Scheme and all share options and share awards to be granted under any other share option schemes and/or share award schemes involving issuance of new Shares adopted and to be adopted by the Company from time to time
“Shareholder(s)”	holder(s) of Share(s)
“Share(s)”	ordinary share(s) in the capital of the Company with nominal value of US\$1/120,000 each
“substantial shareholder”	has the meaning ascribed thereto under the Listing Rules

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, March 25, 2026

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Sherry Xuejun Gu as executive Directors; Dr. Ge Li, Mr. Yanling Cao and Ms. Jingwen Miao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.

* *For identification purpose only*